Download Free Medical Gestational Trophoblastic Disease

Gestational Trophoblastic Disease - GTD PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Gestational Trophoblastic Disease, which is titled "Gestational Trophoblastic Disease - GTD", to know about Gestational Trophoblastic Disease/ Tumors (GTD/ GTTs).

Tags : Gestational Trophoblastic Disease, GTD, Tumors, GTT, trophoblastic cells, Hydatidiform mole, Invasive mole, Choriocarcinoma, Placental site Trophoblastic Tumor

Published on : May 18, 2021 | Views : 3088 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Gestational Trophoblastic Disease YASHODHARA PRADEEP Prof., OBGYN QMH CSMMU LKO
Slide 2-

Classification of GTT GTD Epidemiology, Pathogenesis, Aetiology, β hCG, Clinical Features of Premalignant(GTD) Complete Mole(CM); Partial Mole Management of Complete Mole, or Partial Mole Post evacuation Follow up , Chemotherapy Contraception Clinical Features of Malignant (GTN) Invasive Mole, Placental site tropho blastic tumor( PSTT) Chorio CA Investigations GTN ChorioCA Diagnosis, Investigation, Management Chemotherapy Follow up
Slide 3-

Introduction Gestational Trophoblastic disease is a term used to describe the heterogeneous group of interrelated lesions that arise from abnormal proliferation of placental trophoblast. GTD Lesions are histologically different and can be Benign and malignant.
Slide 4-

WHO Classification GTD Premalignant Diseases Complete Hydatidiform Mole ( C M ) Partial Hyadatidiform Mole ( P M ) Malignant Diseases (Gestational Trophoblastic Neoplasia) Nonmetastatic Invasive Mole Placental site trophoblastic tumor ( PSTT ) Epitheloid tumour Metastatic Gestational Choriocarcinoma
Slide 5-

Epidemiology It is common in oriental countries- Philippines, China, Indonesia, Japan, India, Central and Latin America and Africa. Highest incidence- Philippines- 1 in 80 pregnancies Lowest incidence- Europe- 1 in 752 pregnancies India- 1 in 400 pregnancies Calculated Incidence of complete mole- 1 in 1945 pregnancies partial mole- 1 in 695 pregnancies Age C Ms most common at the extremes of reproductive age The incidence of CM rises fm I:1000 to 1:76; 1:6.5 in subsequent pregnancies CM is the most common antecedent to Chorio CA. But it can occur after any type of pregnancy 3% after invasive mole; 16% after CM
Slide 6-

Homozygous 85% Pathogenesis of complete H Mole
Slide 7-

Pathogenesis of complete H Mole Heterozygous 15%
Slide 8-

Pathogenesis of Partial H. Mole
Slide 9-

Genetic & Pathology C M Always contains Paternal DNA alone so androgenic Macroscopically like bunch of grapes P M are Triploidy two paternal & one maternal sets of chromosomes hyperplasia of chorionic villi with embryo usually dies 8-9 weeks of gestation P57 cycline dependent kinase inhibitor paternally imprinted gene which is maternally expressed P57 kip2 immunostaining is negative in CM in contrast to PMs Hydropic abortions & normal placenta Invasive mole can be diagnosed by USG & rising titers of hCG Presence of chorionic villi distinguish Invasive mole from Choriocarcinoma Chorio CA. Grossly abnormal karyotypes with diverse ploidies PSTT are rare slow growing malignant tumor; intermediate trophoblast from cytotrophoblast produce little hCG Gestational Trophoblastic Disease
Slide 10-

Aetiological factors Genetic factor: Autosomal recessive Genomic Imprinting; Abnormal Methylation In cases of Familial recurrent molar pregnancy; Defective locus at 19q 13.4 at single gene NALP7 , it is member of CATERPILLAR family involved in inflammation & Apoptosis in genetic CM Three other genes H19, P57, IGF-2 Chorio CA. heterozygosity at specific genes deletion 7p12-q11.2; Amplification of 7q21-q31 region ; loss of 8p12-p21 Breast & ovarian cancer also show the abnormalities in heterozygosity in amplification at 7q21-q31 , & loss of 8p12-p21
Slide 11-

Human chorionic gonadotrophin Beta hCG is pituitary/ placental glycoprotein Commercially available Beta hCG test based on sandwich assay principle & rely on two antibodies Rare chance of false negative or false positive results with Rabit polyclonal antibodies RIA used in both serially diluted urine & blood samples . Sensitivity of this test in serum is 1 IU/L, in urine 20 IU/L Beta h CG is tumor marker New Assay are in research Hyperglycosylated hCG (hCG-H ) specific for cases subsequently require chemotherapy (Clinical GTDs ) Cole etal 2006a
Slide 12-

Beta h CG as Tumor marker Half life is 24-36 hrs Marker for pregnancy ,GTD, Germ cell tumors & 15% of epithelial ovarian malignancies H CG levels are also associated with tumor volume 5 IU/l corresponds to 104-105 viable tumor size Beta hCG used as prognostic marker & progression of disease or response to therapy, drug resistance at earlier stage. hCG is best tumor marker known
Slide 13-

Clinical features Complete Mole Most common in first trimester or early Second trimester Vaginal bleeding is the most common symptom (84-97%) Uterus is larger than POG (28%) Presents with the features of threatened abortion; Amenorrhea, pain & bleeding P/V Associated features of Hyperemesis Gravidarum Requires Antiemetic , IV fluids etc Toxaemia or PET 10-15% hyperthyroidism 7%
Slide 14-

Clinical features Theca leutin cysts Beta h CG levels > 100.000 O/E Passage of grapes like vesicle or spontaneous expulsion of entire mole Pulmonary , cervical, Vaginal metastasis may occur disappears after evacuation of mole The presence of metastasis does not necessarily imply invasive mole or chorio CA Macroscopic features: Bunch of grapes due to villous swelling Branching contain hyperplastic cyto & syncytio trophoblast with many vessels
Slide 15-

Complete Molar Pregnancy
Slide 16-

High Risk For Developing Post molar tumor Patients presenting with any of the following signs of marked trophoblastic proliferations hCG Levels > 100,000 mIU/L Excessive Uterine Enlargement Theca leutin cyst 6cm or larger
Slide 17-

Clinical features PARTIALMOLE Findings not as characteristic as in CM Most commonly presents in late Ist or second trimester Uterus is often not enlarged more than POA More often presents as Missed or incomplete abortion Pre evacuation h CG levels are not more than 100,000IU/ L Macoscopic : villous swelling is less intense Embryo is present Microscopic: Trophoblastic hyperplasia, indented outlines & round inclusions Presence of nucleated RBS of embryo in villous structure Due to Early demise of embryo less documentation of PM
Slide 18-

Management Of Molar Pregnancy There are 2 important basic lines: Evacuation of the mole Regular follow up to detect persistent Trophoblastic disease If both basic lines are done appropriately, mortality rates can be reduced to zero.
Slide 19-

Management of Molar Pregnancy For complete mole: Suction Curettage Procedure: 1. Emergency tray should be ready and blood should be handy. 2. Oxytocin infusion: begun before induction of anaesthesia. 3.Cervical dilation
Slide 20-

Management 4. Suction curettage: Suction canula up to a maximum of 12 mm is usually sufficient to evacuate all complete molar pregnancies. If the uterine size is larger than 14 weeks of gestation, one hand should be placed on top of fundus and uterus should be massaged to stimulate uterine contraction and reduce the risk of perforation. 5. Sharp curettage: gentle sharp curettage is done to remove any residual molar tissue. Cervical preparation with prostaglandins or misoprostol should be avoided to reduce the risk of embolisation.
Slide 21-

Should products of conception be examined histologically? Histological examination is indicated in: Failed pregnancies (missed or molar): all medically or surgically managed cases Products of conception obtained after all repeat evacuations (post abortive or post partum). There is no need after therapeutic termination: provided that foetal parts are identified on USG A urine pregnancy test should be performed 3 weeks after medical management of failed pregnancy if products of conception are not sent for histological examination.
Slide 22-

Anti-D Prophylaxis (RCOG) NOT required in Complete Mole: because of poor vascularisation of the chorionic villi and absence of the D-antigen. Required in: -partial mole: due to presence of RBCs -complete mole: if diagnosis is not confirmed histopathologically.
Slide 23-

Second uterine evacuation There is NO clinical indication for the routine use of second uterine evacuation. It may be useful for symptom control in selected patients with heavy bleeding or curative if the recurrent molar tissue is confined to the uterine cavity, particularly in those with hCG levels <1500 IU/L.(Recent Advances)
Slide 24-

Post Evacuation Surveillance Done to detect persistent trophoblastic disease (GTN) A baseline serum βhCG is obtained within 48 hours after evacuation Levels are monitored every 2 weeks until normalisation and urine βhCG levels analysed monthly after this. These levels should progressively fall to an undetectable level (<5 mu/ml). The average time to achieve the first normal β-hCG level after evacuation is about 9 weeks. If symptoms are persistent, more frequent βhCG estimation and USG examination ± second evacuation is advised.
Slide 25-

Optimum follow up period following normalization of β hCG If βhCG has reverted to normal in ≤56 days (8 weeks) of the pregnancy event: follow up is for 6 months from the date of uterine evacuation. >56 days of the pregnancy event: follow up is for 6 months from normalisation of hCG level. All women should notify at the end of any future pregnancy, whatever the outcome of the pregnancy. β hCG levels are measured 6-8 weeks after the end of pregnancy to exclude disease occurrence.
Slide 26-

Contraception Should NOT conceive until follow up is complete. Use Barrier method until hCG revert to normal (?OCPs may act as growth factor for trophoblastic tissue). Once hCG has normalised, the combined oral contraceptive pill may be used. IUCD should not be used until hCG levels are normal to reduce the risk of uterine perforation.
Slide 27-

Role of hysterectomy If the patient desires surgical sterilization, a hysterectomy may be performed with the mole in situ. Hysterectomy does not prevent metastasis; therefore, patients will require follow up with assessment of hCG levels. The ovaries may be preserved at the time of surgery, even in the presence of prominent theca luiten cysts.
Slide 28-

Role of prophylactic chemotherapy The long term prognosis for women with a H. Mole is not improved with prophylactic chemotherapy. Because toxicity- including death- may be significant, it is not recommended routinely (ACOG 2004). It may be useful in the high-risk cases when follow up are unavailable or unreliable. HIGH RISK FACTORS: hCG level >100,000 mIU/ml Excessive uterine enlargement Theca lutien cysts 6 cm in diameter
Slide 29-

Chances of malignant transformation Complete H.Mole 16% Partial H.Mole 0.5%
Slide 30-

Gestational trophoplastic Neoplasia Nonmetastatic Invasive Mole: Clinical features Clinical diagnosis by persistence or rising titers of Beta h CG in the weeks after molar evacuation & USG Persistent bleeding p/v Lower abdominal pain due to invasion in myometrium, vulva, vagina or intra abdominal metastasis It may spread to adjacent pervic structures bladder , rectum; hematuria, bleeding P/ R Pulmonary metastasis Mostly due to initial diagnosis of CM is missed & not on Beta h CG follow up
Slide 31-

Clinical features Placental Site Trophoblastic Tumor (PSTT): it is rare slow growing tumor Women mainly presents with menstrual irregularities & lower abdominal pain, galactorrhea due to hyperprolactinemia increased h PL Little or no h CG is produced ( Free B hCG fragment ) Rarely presents as nephrotic syndrome, hematuria or DIC Spread is late local Infiltration & metastasis is through lymphatic Microscopically: In the normal placenta it is distinct from villous trophoblast & infiltrates the decidua, myometrium, & spiral arteries. Mainly from intermediate trophoblast derived fm cytotrophoblast
Slide 32-

Metastatic Gestational Trophoblastic Neoplasia Second most common GTN 1 in 30,000 pregnancies Early haematogenous spread is characterstic of choriocarcinoma 40% after molar pregnancy: Easily Diagnosed 60% non-molar pregnancy: Difficult to Diagnose
Slide 33-

GTN arises when the normal regulatory mechanisms controlling the proliferation and invasiveness of trophoblastic tissue are lost. Diagnosis of the GTN is made on Clinical presentation Elevated b-HCG Evidence of metastasis Imaging Tissue for Histology- Seldom obtained (Definitive Histological Diagnosis of type of GTN is not made in most cases). Metastatic Gestational Trophoblastic Neoplasia
Slide 34-

Metastatic Gestational Trophoblastic Neoplasia CHORIOCARCINOMA: Clinical features Occurs mainly following any form of pregnancy, mainly after CM Difficult to differentiate from Invasive mole as H/P is not possible Clinical features of bleeding p/v , lower abdominal pain, or in 1/3 of cases no pelvic symptoms but symptoms of distant metastasis lungs , brain ,liver, skin, cauda equina & the heart may present Highly malignant , appears as soft purple largely hemorrhagic mass
Slide 35-

Clinical features of chorio CA Microscopic: implanting blastocyst with central cores of mononuclear cytotropho surrounded by rim of multinucleated syncytiotrophoblast & distinct absence of chorionic villi extensive areas of necrosis & haemorrage &frequent evidence of tumor in the sinuses The hypervascularity & absence of connective tissue support are the reason for its highly malignant behaviour DIAGNOSIS IS ALWAYS BY BETA h CG
Slide 36-

investigations Quantitative beta hCG X Ray Chest Pelvic Doppler USG Abdominal doppler USG to rule out liver & renal metastasis CT chest , abdomen MRI brain Beta h CG in cerebrospinal fluid PET FD PET Genetic studies
Slide 37-

Which women should be investigated for Persistent GTD after a non molar pregnancy? (RCOG Guideline) Any women who develops persistent vaginal bleeding after a pregnancy event. A urine pregnancy test should be performed in all cases of persistent or irregular vaginal bleeding after a pregnancy event. Symptoms from metastatic disease, such as dyspnoea or abnormal neurology, can occur very rarely.
Slide 38-

FIGO REQUIREMENT FOR MAKING DIAGNOSIS OF GTN Four values or more of plateaue hCG over at least 3 weeks: days 1, 7, 14 and 21. A rise of hCG of 10% or greater for 3 values or more over at least 2 weeks: days 1, 7, and 14. Histologic diagnosis of choriocarcinoma. Persistence of hCG beyond 6 months after mole evacuation.
Slide 39-

Invasive H. Mole Myometrial invasion Sometimes involving the peritoneum, parametrium, or vaginal vault. Originate almost always from H. mole Vesicles
Slide 40-

Metastatic disease
Slide 41-

If the pelvic examination & chest X-ray are negative, it is very uncommon to have metastatic involvement of other sites. Metastatic Disease
Slide 42-

Chest X ray: widespread metastatic lesions.
Slide 43-

GTN Vaginal Metastasis
Slide 44-

Cranial MRI scan: Large metastasis on the left (black arrows) Brain MRI of a patient with a solitary brain metastasis in remission
Slide 45-

Autopsy specimen Multiple hemorrhagic hepatic metastasis CT Scan: Liver metastsis
Slide 46-

Prognostic score is central to the management of GTN. A single universally accepted, anatomical staging and prognostic scoring system for GTN was developed by FIGO in 2000. Management of GTN
Slide 47-

ANATOMIC FIGO STAGING SYSTEM FOR GTN (2000)
Slide 48-

ppt slide no 48 content not found
Slide 49-

WORK UP OF GTN History & physical examination Serial weekly hCG measurement in serum. Hemogram, LFT, KFT Chest X-ray USG whole abdomen pelvis to rule out hepatic and renal metastasis CT or MRI brain CSF analysis – in metastatic disease. PET FDG PET Curette to be done if there is uterine bleeding. There is grave dangerous of hemorrhage at the biopsy site.
Slide 50-

GTN Low risk (<6) High risk (> 6) Single-agent chemotherapy Combination chemotherapy Resolution Life-long hCG follow-up Relapsed/resistant disease Second-line chemotherapy+ surgical debulking
Slide 51-

Low Risk GTN FIGO score 6 or less. FIGO stage I, II & III. Drugs schedules: single agent chemotherapy Most commonly used regimen. Methotrexate: 1 mg/kg 1M on days 1, 3, 5, 7 Folinic acid 0.1 mg/kg 1M on days, 2, 4, 6 and 8. Side Effects: Stomatitis, conjunctivitis, abdominal and chest pain. Actinomycin- D: (primary therapy in case of abnormal liver function)
Slide 52-

Role of hysterectomy in non metastatic disease i.e. Stage-I If patient does not wish to preserve fertility hysterectomy with adjuvant single agent chemotherapy given. In case of stage-I PSTT. Role of adjuvant chemotherapy. Decrease dissemination of viable tumor cells at surgery. Maintain cytotoxic level of chem. To treat any occult metastasis.
Slide 53-

Follow up in Low risk GTN Weekly hCG titre until normal for 3 consecutive weeks. Monthly  HCG level until normal for 12 consecutive months. Effective contraception during the follow up (OCP) FIGO recommends additional 2 courses of chemotherapy after initial negative  hCG.
Slide 54-

High Risk GTN Stage I, II, III With FIGO score 7 or greater or Stage IV . Primary intensive combination chemotherapy and selective use of radiation and surgery. Regimes given : MAC. Modified Bagshawe (CHAMOCA) EMA-CO EMA-EP. .
Slide 55-

MAC-III Regime Mtx 1 mg/kg IM/1V Days 1, 3, 5, 7 Folinic acid 0.1 mg/kg IM Days 2, 4, 6, 8 Actinomycin-D 12 g/kg IV Days 1-5 Cyclophosphamide 3 mg/kg IV Days 1-5 To be repeated every 15 days if toxicity permits.
Slide 56-

EMA-CO Regime Etoposide, methotrexate, actinomycin D, alternating weekly with cyclophosphamide and oncovin. Day 1 Actinomycin D 500 micrograms IV push new IV. Etoposide 100 mg/m2 over 30-50 min. Methotrexate 100 mg/m2 IV infusion over 1 hr and then Methotrexate 200 mg/m2 IV infusion over 12 hrs Day 2 Actinomycin D 500 micrograms IV push new IV Etoposide 100 mg/m2 over 30-50 min. Folinic acid 15 mg IV push Q 6 hrs for 8 doses beginning 24 hrs after methotrexate bolus. Day 8 Vincristine (Oncovin) 1 mg/m2 IV Cyclophosphamide 600 mg/m2 IV SIDE EFFECT:- Myelosuppresion ,Mucositis , Neuropathy ,Reversible alopecia
Slide 57-

EMA-EP In patient resistant to EMA-CO On day 8 Etoposide- 10 mg/m2 iv. Cisplatin- 80 mg/m2 iv treatment – until 3 consecutive weekly titres normal. 2-4 cycles given further after initial normal  H.C.G. .
Slide 58-

Chemotherapy Should Not Be Repeated Unless WBC > 3000/cu mm Polymorph > 1500/ cu mm Platelets > 100,000/ cu mm BUN, SGOT, SGPT are normal No febrile course No oral or GIT ulceration
Slide 59-

Follow up OF High risk GTN Weekly HCG until normal for 3 consecutive weeks. Monthly HCG for 24 consecutive months. Contraception in follow up period.
Slide 60-

Management of sites of metastasis VAGINAL &PELVIS -30% Single agent chemotherapy –Low risk Combination chemotherapy –High risk If bleeding occurs- Vaginal packing Wide local excision Arteriographic embolisation of hypogastric arteries
Slide 61-

PULMONARY-80% Present as – Chest pain, cough, hemoptysis dyspnoea. X-ray features- Snowstorm Discrete round densities. Pleural effusion Embolic pattern Rx Single agent chemotherapy-low risk. Combination – high risk. Thoracotomy-viable pulmonary Metastasis following combination chemotherapy.
Slide 62-

HEPATIC-10% Worse prognosis. Usually associated with widespread metastasis Intraperitoneal bleeding may occur. Rx Chemo & concurrent radiation (2000-3000 cGy). Hepatic resection to excise resistant foci. Cerebral-10% Acute focal neurological deficits. Combination chemo + WBRT (2000-3000). Patients with metastasis on initial evaluation respond better than who develop Lesion during therapy. During period of WBRT- Mtx in EMA-CO be increased to 1 g/m2 with Folinic.Acid rescue. .
Slide 63-

SURVEILLANCE DURING AND AFTER THERAPY OF GTN . (DISAIA Gynaecolog oncology 2007)
Slide 64-

ppt slide no 64 content not found
Slide 65-

ppt slide no 65 content not found
Slide 66-

CONTRACEPTION During follow up period I. OCP’s Safe Started soon after evacuation of H. mole. Given during the entire period of follow up. No increased risk of postmolar GTN or rate of decline of hCG titre with OCPs use. II. Barrier methods Safe alternative to OCP’s in patients whom OCP are contraindicated. III. IUCD Contraindicated due to an increased risk of uterine perforation . . DISAIA Gynaecology oncology 2007
Slide 67-

Future Child Bearing Pregnancy outcomes in patient with history of molar gestation are similar to patient with no such history with respect to live birth 1st and 2nd trimester abortion, anomalies, Stillbirth, pre-maturity and Caesarean rate. Pregnancy outcome is similar irrespective of complete or partial mole. For subsequent pregnancy. Ist trimester TVS to confirm normal pregnancy. HCG 6 wks after termination of pregnancy . After effective treatment for non-malignant GTN molar pregnancy occur in 1-2% subsequent pregnancies. .DISAIA Gynaecology oncology 2007
Slide 68-

Treatment of malignant GTN with Chemotherapy is compatible with preservation of fertility and not assess with increased risk of congenital malformations. Women undergoing I.U.I. after previous molar gestations, occasionally develops repeated moles. This is due to an oocyte defect predisposing to abnormal fertilization. Therapeutic alterations are: ICSI with pre-implementation genetic diagnosis Donor oocyte IVF
Slide 69-

Co-Existence of normal pregnancy and GTN Described in both spontaneous & IVF gestations. Estimated incidence of twin pregnancy with 1 mole and 1 fetus 1 per 221,000-1,00,000 or > 125 cases reported. Diagnosis difficult based on imaging alone. In many cases diagnosis made only after termination of pregnancy. Increased risk for haemorrhage persistent GTN and medical complications. Pregnancy coexistent with H. mole need be termination. Usually preterm delivery is often required because of complications like bleeding or preeclampsia.
Slide 70-

Thank You